NASDAQ:MRTX

Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference

Retrieved on: 
Thursday, April 27, 2023
Webcast, Bank, Therapy, Mirati Therapeutics, Conference, SAN, Pharmaceutical industry, Broadcasting

SAN DIEGO, April 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T.

Key Points: 
  • SAN DIEGO, April 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T.
  • Ben Hickey , chief commercial officer, will represent the company in a fireside chat at the conference.
  • Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com .
  • A replay of the webcast will be made available following the event.

Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023

Retrieved on: 
Tuesday, April 25, 2023
Mirati, Therapy, Mirati Therapeutics, SAN, Communications satellite, Broadcasting, Cryptocurrency

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023.

Key Points: 
  • SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023.
  • During a conference call at 4:30 p.m.
  • ET / 1:30 p.m. PT on May 9, company executives will provide company updates and review financial results.
  • A replay of the call will be available approximately 2 hours after the event has ended at the same website.

Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs

Retrieved on: 
Monday, April 3, 2023
MTAP, AACR, MTA, Neoplasm, SOS1, American Association for Cancer Research, Mirati Therapeutics, Experiment, Congress, EGFR, SAN, Mirati, Therapy, Poster, PRMT5, Pharmaceutical industry, Communications satellite

SAN DIEGO, April 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRASG12C inhibitor, or an epidermal growth factor receptor (EGFR)  inhibitor (e.g. osimertinib).

Key Points: 
  • Findings will be presented on April 17 at the American Association for Cancer Research (AACR 2023) Annual Congress as an oral presentation at 3:36 p.m. -3:51 p.m.
  • ET / 12:36 p.m.- 12:51 p.m. PT (Presentation #3499) during the Molecular Pathway Discovery and Translation in Solid Tumors mini session.
  • The full abstract for the presentation can be found here .
  • In addition, Mirati will share poster presentations featuring MRTX1719, the company's novel MTA cooperative PRMT5 inhibitor.

Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference

Retrieved on: 
Monday, March 6, 2023
Mirati Therapeutics, Conference, Therapy, Webcast, SAN, Mirati, Pharmaceutical industry, Broadcasting

SAN DIEGO, March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T.

Key Points: 
  • SAN DIEGO, March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T.
  • Ben Hickey , chief commercial officer, and Alan Sandler , chief medical officer, will represent the company in a fireside chat at the conference.
  • Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com .
  • A replay of the webcast will be made available following the event.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the Firm

Retrieved on: 
Monday, February 27, 2023
Mirati, Mirati Therapeutics, Acquisition

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ: MRTX) on behalf of the company’s long-term investors.

Key Points: 
  • PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ: MRTX) on behalf of the company’s long-term investors.
  • Mirati shareholders are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.)
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023

Retrieved on: 
Tuesday, February 14, 2023
Mirati, SAN, Mirati Therapeutics, Therapy, Cryptocurrency, Broadcasting

SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023.

Key Points: 
  • SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023.
  • During a conference call at 4:30 p.m.
  • ET / 1:30 p.m. PT on February 28, company executives will provide company updates and review financial results.
  • A replay of the call will be available approximately 2 hours after the event has ended at the same website.

Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences

Retrieved on: 
Wednesday, February 1, 2023
Mirati, SAN, PT, Mirati Therapeutics, Therapy, Webcast, Conference

SAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate in two upcoming healthcare conferences.

Key Points: 
  • SAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate in two upcoming healthcare conferences.
  • ET at the Guggenheim Healthcare Talks: Oncology Day Conference.
  • Laurie Stelzer , chief financial officer, and Alan Sandler , chief medical officer, will represent the company in a fireside chat at the conference.
  • Laurie Stelzer , chief financial officer, and Ben Hickey , chief commercial officer, will represent the company in a fireside chat at the conference.

Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133

Retrieved on: 
Thursday, January 19, 2023
Therapy, Doctor of Philosophy, Half-life, Investigational New Drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mutation, FDA, SAN, Prevalence, Drug discovery, Drug, Patient, Food, Lung, Pharmaceutical industry, Vaccine, IND, Mirati

SAN DIEGO, Jan. 19, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a potential first-in-class oral KRASG12D selective inhibitor for clinical evaluation. KRASG12D mutations impact approximately 180,000 patients in the US and Europe, representing approximately a 2.5-fold increase in prevalence compared to KRASG12C mutations. No targeted oncology treatment options currently exist for these patients.

Key Points: 
  • KRASG12D mutations impact approximately 180,000 patients in the US and Europe, representing approximately a 2.5-fold increase in prevalence compared to KRASG12C mutations.
  • MRTX1133 is a highly potent investigational inhibitor of the KRASG12D driver mutation and demonstrated selective and reversible inhibition of KRASG12D in both its active and inactive states.
  • In addition, MRTX1133 administration resulted in marked tumor response in preclinical KRASG12D mutated pancreatic cancer models as well as lung and colorectal cancer models.
  • The Phase 1/2 clinical trial will launch in early 2023 with plans for multiple expansion cohorts in pancreatic, colorectal, lung and other KRASG12D tumor types.

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, January 6, 2023
RSU, Therapy, SAN, Employment, Pharmaceutical industry, Life insurance, Health insurance, Mirati

SAN DIEGO, Jan. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 6 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company.

Key Points: 
  • SAN DIEGO, Jan. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 6 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 9,010 shares of Mirati's common stock, and in the aggregate 5,780 restricted stock units ("RSUs").
  • The options have an exercise price of $46.65 per share, which is equal to the closing price of Mirati's common stock on January 3, 2023, (the "Grant Date").

Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 22, 2022
Patient, TAM, Webcast, SAN, Judgement, PRMT5, Life, Conference, SOS1, Lung cancer, Therapy, Science, Cancer, MTA, Pharmaceutical industry, Mirati

SAN DIEGO, Dec. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023.

Key Points: 
  • SAN DIEGO, Dec. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023.
  • David Meek , chief executive officer, will make a formal presentation, and answer questions about the Company at 9:00 a.m. P.T.
  • Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com .
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").